| mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
0.34 |
5e-20 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.29 |
1e-19 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.31 |
4e-18 |
| mRNA |
GSK1070916 |
GDSC1000 |
pan-cancer |
AAC |
0.3 |
2e-16 |
| mRNA |
decitabine |
CTRPv2 |
pan-cancer |
AAC |
0.26 |
2e-16 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.28 |
4e-16 |
| mRNA |
alisertib |
CTRPv2 |
pan-cancer |
AAC |
0.29 |
9e-16 |
| mRNA |
PX-12 |
CTRPv2 |
pan-cancer |
AAC |
0.26 |
8e-15 |
| mRNA |
NPK76-II-72-1 |
GDSC1000 |
pan-cancer |
AAC |
0.26 |
9e-15 |
| mRNA |
Mitomycin-C |
CTRPv2 |
pan-cancer |
AAC |
0.3 |
1e-14 |